Omega-3 Fatty Acids Are Not Simply Anti-Inflammatory — They Are Precursors to Specialized Pro-Resolving Mediators (Resolvins, Protectins, Maresins) That Actively Terminate Inflammation, and the REDUCE-IT Trial Showed Pure EPA at 4g/Day Reduced Major Cardiovascular Events by 25% in High-Triglyceride Patients on Statins While the STRENGTH Trial's Neutral Result May Reflect a Flawed Mineral Oil Comparator Rather Than a Failure of EPA+DHA
Updated: June 2026omega-3 · fish oil · EPA · DHA · omega-3 benefits · fish oil benefits · omega-3 heart health · omega-3 cardiovascular · omega-3 inflammation · omega-3 anti-inflammatory · EPA DHA · eicosapentaenoic acid · docosahexaenoic acid · omega-3 triglycerides · omega-3 and TG · omega-3 triglycerides reduction · REDUCE-IT · REDUCE-IT trial · Bhatt 2019 · REDUCE-IT NEJM · icosapentaenoic acid · Vascepa · Vascepa trial · EPA-only omega-3 · icosapentaenoic acid cardiovascular · Vascepa cardiovascular · Vascepa MACE · REDUCE-IT 25 percent · REDUCE-IT cardiovascular death · REDUCE-IT results · REDUCE-IT criticism · REDUCE-IT mineral oil · STRENGTH trial · STRENGTH trial omega-3 · STRENGTH trial neutral · EPA DHA trial · omega-3 cardiovascular trial · mineral oil comparator omega-3 · STRENGTH vs REDUCE-IT · ASCEND trial · VITAL omega-3 · omega-3 and heart disease · omega-3 clinical trials · SPM · specialized pro-resolving mediators · resolvins · protectins · maresins · resolvin D1 · resolvin E1 · omega-3 resolvins · DHA resolvins · EPA resolvins · omega-3 inflammation resolution · omega-3 active resolution · resolvins and inflammation · omega-3 not just anti-inflammatory · SPM supplements · omega-3 specialized pro-resolving mediators · EPA vs DHA · EPA and DHA difference · EPA for heart · DHA for brain · EPA vs DHA function · DHA brain · DHA cognitive · DHA neural · DHA membrane · EPA cardiovascular · EPA triglycerides · EPA and LDL · EPA blood pressure · DHA vs EPA which is better · EPA triglyceride lowering · EPA VLDL · omega-3 TG mechanism · algal oil · algal oil DHA · algae omega-3 · vegan omega-3 · plant-based omega-3 · algal oil vs fish oil · algal oil DHA bioavailability · algal DHA · DHA algae · vegan DHA · vegetarian omega-3 · algal oil sustainability · fish oil oxidation · oxidized fish oil · fish oil rancid · fish oil TOTOX · TOTOX value · TOTOX fish oil · primary oxidation peroxide value · secondary oxidation ANISIDINE value · fish oil quality · best fish oil · fish oil freshness · how to check fish oil quality · fish oil burp · fish oil absorption · fish oil with food · fish oil triglyceride form · fish oil ethyl ester · triglyceride fish oil vs ethyl ester · omega-3 bioavailability forms · omega-3 dosage · how much omega-3 · omega-3 2g per day · omega-3 4g per day · therapeutic omega-3 dose · omega-3 for heart · omega-3 for triglycerides · omega-3 blood thinning · omega-3 and anticoagulants · omega-3 and surgery · omega-3 mercury · mercury in fish oil · fish oil heavy metals · omega-3 pregnancy · DHA pregnancy · omega-3 third trimester · omega-3 and depression · omega-3 mental health · omega-3 atrial fibrillation · omega-3 AFib · REDUCE-IT AFib signal
The omega-3 fatty acids EPA (eicosapentaenoic acid, 20:5 n-3) and DHA (docosahexaenoic acid, 22:6 n-3) are long-chain polyunsaturated fatty acids that cannot be synthesized de novo in adequate quantities by the human body and must be obtained from dietary sources (primarily oily fish, shellfish) or supplements. They are commonly grouped as "fish oil" in supplement form, but they have meaningfully distinct biochemical roles: EPA is the primary substrate for eicosanoid synthesis (prostaglandin E3, thromboxane A3, leukotriene B5 — all less inflammatory than their n-6-derived counterparts) and the primary precursor for E-series resolvins; DHA is the dominant structural lipid of neuronal membranes (comprising ~40% of brain gray matter fatty acids), the retina, and the testes, and is the primary precursor for D-series resolvins, protectins, and maresins. The ALA (alpha-linolenic acid) found in flaxseed, chia, and walnuts is a plant-sourced n-3 but is poorly converted to EPA (<8%) and DHA (<0.5–4%) in adults — it does not substitute for preformed EPA and DHA for cardiovascular or inflammatory purposes.
The long-held model of omega-3 action — that EPA and DHA are simply "anti-inflammatory" by competing with arachidonic acid (n-6) for COX and LOX enzymes, producing less inflammatory eicosanoids — is now understood to be incomplete. The more sophisticated picture, pioneered by Charles Serhan at Harvard, involves the biosynthesis of specialized pro-resolving mediators (SPMs): a class of lipid-derived molecules (resolvins, protectins, maresins, lipoxins) that do not merely suppress inflammation but actively orchestrate its resolution — a fundamentally different and physiologically distinct process from prevention or suppression of the inflammatory cascade.
−25% MACE
REDUCE-IT — the landmark omega-3 cardiovascular trial: Bhatt DL et al. (2019, NEJM): REDUCE-IT (Reduction of Cardiovascular Events with Icosapentaenoic Acid–Intervention Trial); DESIGN: double-blind RCT; N=8,179 statin-treated patients with elevated triglycerides (135–499 mg/dL) and either established cardiovascular disease or diabetes + ≥1 additional cardiovascular risk factor; INTERVENTION: icosapentaenoic acid (EPA-only, Vascepa) 4g/day vs mineral oil placebo; follow-up: median 4.9 years; PRIMARY ENDPOINT: MACE (major adverse cardiovascular events: CV death, nonfatal MI, nonfatal stroke, coronary revascularization, unstable angina hospitalization); RESULTS: MACE: −25% (HR 0.75, 95% CI 0.68–0.83, p<0.001); CV death: −20% (HR 0.80); fatal and nonfatal MI: −31%; fatal and nonfatal stroke: −28%; urgent coronary revascularization: −35%; MECHANISM: triglyceride lowering was significant (−19% from baseline) but does not fully explain the 25% risk reduction (the magnitude exceeds what TG lowering alone would predict); EPA membrane incorporation may stabilize plaque, reduce platelet aggregation via thromboxane A3 vs A2, and reduce oxidative stress in vascular walls; EPA's anti-inflammatory effects at 4g/day clinical dose likely exceed what 1–2g/day achieves; ATRIAL FIBRILLATION SIGNAL: dose at 4g/day EPA significantly increased AF risk (+31%); AF incidence: 5.3% EPA vs 3.9% placebo — this finding is replicated in other high-dose omega-3 trials and is a meaningful clinical caveat at pharmacological doses; at standard supplement doses (1–2g/day EPA+DHA), the AF risk increase appears much smaller and may not be clinically significant
STRENGTH Trial
the neutral trial and the mineral oil controversy: Nicholls SJ et al. (2020, JAMA): STRENGTH (Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh CV Risk PatienTs with Hypertriglyceridemia); DESIGN: RCT, N=13,078; INTERVENTION: omega-3 carboxylic acids (EPA+DHA, Epanova) 4g/day vs corn oil placebo; follow-up: median 3.5 years (stopped early for futility); RESULT: no significant reduction in MACE (HR 0.99, p=0.92) — essentially flat; WHY DOES REDUCE-IT (EPA only) SHOW 25% BENEFIT WHILE STRENGTH (EPA+DHA) SHOWS ZERO?: several hypotheses: (1) MINERAL OIL COMPARATOR IN REDUCE-IT: the placebo in REDUCE-IT was mineral oil, not an inert substance; mineral oil may have: increased LDL-C by ~6 mg/dL (by interfering with dietary fat absorption and disrupting statin absorption); increased hsCRP (inflammatory marker) modestly; these effects in the placebo arm could have artifactually amplified the apparent benefit of EPA; analysis of mineral oil controversy is ongoing; studies suggesting it was benign vs studies suggesting real harm exist; (2) EPA vs DHA antagonism: DHA at high doses competes with EPA for phospholipid incorporation and may attenuate some EPA-specific cardiovascular effects; (3) FORM: Epanova uses free fatty acid form (absorbed differently than Vascepa's ethyl ester form — but free fatty acid is actually better absorbed, so this argues against Epanova being inferior by absorption); (4) DOSE DIFFERENCE in EPA specifically: REDUCE-IT had 4g pure EPA; STRENGTH had a mixture with lower EPA content per dose; CURRENT CONSENSUS: cardiologists are split; FDA approved Vascepa for CV risk reduction post-REDUCE-IT; many consider the mineral oil confound non-trivial; ASCEND trial (2018, NEJM): N=15,480 diabetic patients, omega-3 1g/day (EPA+DHA), −11% serious vascular events (borderline significant, p=0.055); consistent with lower-dose benefit but with EPA+DHA
SPMs — Resolvins
the active resolution mechanism — beyond anti-inflammation: Serhan CN et al. (2002–2020, Harvard, multiple landmark papers): discovered a family of omega-3-derived lipid mediators that do not suppress inflammation but actively terminate it — a functionally distinct and previously unrecognized process; INFLAMMATION RESOLUTION IS ACTIVE (not passive): unresolved inflammation (failure of resolution) → chronic inflammation → tissue damage; resolution of acute inflammation requires: neutrophil apoptosis and clearance by macrophages; macrophage phenotype switch from M1 (pro-inflammatory) to M2 (pro-resolving/anti-fibrotic); restoration of tissue homeostasis; without active resolution signals, neutrophils persist → tissue injury continues; SPM CLASSES AND OMEGA-3 PRECURSORS: RESOLVINS (E-series): biosynthesized from EPA via COX-2 (aspirin-acetylated form) + 5-LOX pathway; Resolvin E1 (RvE1): inhibits neutrophil transmigration; promotes phagocytosis of apoptotic cells (efferocytosis); reduces TNF-α, IL-12; RESOLVINS (D-series): biosynthesized from DHA via 15-LOX/COX-2 pathway; Resolvin D1 (RvD1): reduces PMN recruitment; promotes macrophage M2 polarization; reduces IL-6, TNF-α; Resolvin D2: reduces organ injury in sepsis models; PROTECTINS: biosynthesized from DHA via 15-LOX; Protectin D1 (Neuroprotectin D1 in the brain): inhibits apoptosis; reduces Aβ-stimulated inflammatory gene expression in Alzheimer models; MARESINS: biosynthesized from DHA by macrophages via 12-LOX; Maresin 1 (MaR1): most potent known pro-resolving mediator; regenerative in tissue repair; promotes tissue regeneration alongside resolution; CLINICAL IMPLICATION: omega-3s work not just by reducing arachidonic acid-derived pro-inflammatory eicosanoids but by increasing the concentration of resolution-promoting SPMs — a gain-of-function benefit that makes omega-3 repletion important independent of baseline inflammation
Fish Oil Oxidation
the quality problem most consumers ignore: omega-3 polyunsaturated fatty acids (EPA and DHA) are highly susceptible to oxidation — they have 5 and 6 double bonds respectively, each a site for free radical attack; OXIDATION STAGES: PRIMARY OXIDATION: molecular oxygen attacks PUFA double bonds → hydroperoxides (peroxides); measured by Peroxide Value (PV); PV <5 meq O₂/kg = acceptable; PV >10 = elevated concern; SECONDARY OXIDATION: hydroperoxides decompose → aldehydes, ketones, alcohols (the "fishy" and "rancid" smell); measured by Anisidine Value (AV); TOTOX VALUE = 2 × PV + AV: total oxidation index; TOTOX <10 = fresh, acceptable; TOTOX 10–26 = borderline; TOTOX >26 = unacceptable for consumption; GOED (Global Organization for EPA and DHA Omega-3s) voluntary standard: TOTOX ≤26, PV ≤5, AV ≤20; WHY IT MATTERS: oxidized omega-3 supplements may not provide cardiovascular benefit and may potentially be pro-inflammatory (oxidized lipids can activate TLR4 and NF-κB); taste/burping is a signal but not reliable — flavored or enteric-coated capsules can conceal oxidized oil; HOW TO ASSESS QUALITY: buy from brands that publish third-party TOTOX results (IFOS certification — International Fish Oil Standards); refrigerate after opening; consume within 60 days of opening; if oil smells fishy when capsule is cut open, it is likely oxidized; FRESHNESS TIP: triglyceride-form fish oil is more stable than ethyl ester form and better absorbed (especially without dietary fat); rTG (re-esterified triglyceride) is the gold standard for absorption and stability; ALGAL OIL: produced by Schizochytrium or Nannochloropsis microalgae (the original omega-3 source in the food chain — fish accumulate EPA/DHA by eating algae); provides DHA (and limited EPA); no mercury, PCBs, or heavy metal concerns (algae are grown in controlled fermentation tanks); comparable bioavailability to fish oil DHA; preferred for vegans, pregnant women avoiding high fish consumption, and those concerned about marine contamination; note: most algal oils are DHA-dominant with low EPA — check the EPA content if EPA-specific effects are desired
Want the full evidence writeup?
The Stack Protocol builds four complete goal stacks — Energy, Focus, Sleep, Longevity — with exact doses, timing, budget tiers, and a 30-day rollout plan, graded with the same evidence framework behind this page.
Get the Stack Protocol → $19
EPA vs DHA: Functions, Sources, and Supplement Forms
| Property | EPA (20:5 n-3) | DHA (22:6 n-3) |
|---|
| Primary functions | Triglyceride lowering; cardiovascular eicosanoids; E-series resolvins; platelet aggregation inhibition | Neuronal membrane structure; retina phospholipids; D-series resolvins, protectins, maresins; fetal brain development |
| REDUCE-IT evidence | 25% MACE reduction at 4g/day (pure EPA) | Not tested in REDUCE-IT (EPA-only trial) |
| Brain penetration | Low (poorly crosses BBB; rapidly oxidized vs incorporated) | High (primary structural fatty acid of brain gray matter) |
| TG lowering | ~19–27% at 4g/day | ~14–22% at 4g/day (slightly less efficient) |
| LDL effect (high dose) | Minimal increase or neutral | May increase LDL-C 5–10 mg/dL at high doses |
| Best food sources | Sardines, mackerel, Atlantic salmon, herring | Salmon, albacore tuna, halibut, algae |
| Vegan source | Limited from algae (Nannochloropsis has EPA) | Algal oil (Schizochytrium, Thraustochytrid) |
| Pregnancy priority | Modest; DHA is the pregnancy priority | Critical: 200mg/day minimum for fetal brain/retinal development |
Omega-3 Protocol — Dosing, Timing, and Quality Selection
Baseline dosing (general health, not cardiovascular indication): 1–2g EPA+DHA per day from a combined supplement; this aligns with the VITAL trial omega-3 arm dose (1g/day — showed borderline −11% vascular events in diabetics, and significant −28% MI reduction in subgroup with low dietary fish consumption); maintenance goal: plasma omega-3 index ≥8% (percentage of EPA+DHA in red blood cell membranes); typical Western diet produces omega-3 index of ~4%; 1–2g/day supplements raise it to ~6–7%; dietary fish (2+ servings of fatty fish/week) can raise it to 8%+; the omega-3 index is measurable via specialized blood tests (Omega Quant or similar) and is increasingly recognized as a cardiovascular risk biomarker.
Therapeutic dosing (cardiovascular indication, high TG): 2–4g EPA+DHA per day; at 4g/day, pharmaceutical prescriptions (Vascepa for pure EPA, Lovaza for EPA+DHA, Epanova for omega-3 carboxylic acids) are significantly more concentrated (90%+ omega-3 content) vs typical consumer fish oil (30–60% omega-3); prescription-grade is preferred at therapeutic doses because consumer fish oil would require 8–12 capsules/day to reach 4g EPA+DHA; the AF risk signal at 4g/day (especially pure EPA) should be discussed with a cardiologist for patients with pre-existing AF or significant AF risk factors; PREGNANCY: DHA 200–600mg/day (algal oil preferred; or low-mercury fish oil); EPA +DHA 1g/day is commonly recommended in pregnancy guidelines; TAKE WITH FAT: omega-3s absorb significantly better with a fat-containing meal (the triglyceride form absorbs better than ethyl ester form without food; both absorb best with fat); AVOID at same time as warfarin/anticoagulants (omega-3s have modest blood-thinning effects at high doses — not significant at 1g/day but worth noting at 4g/day pre-surgery); STORAGE: refrigerate after opening; use within 60–90 days; do not purchase fish oil that has been stored in a warm location (convenience store vs refrigerated pharmacy section).
High-Quality Fish Oil (rTG) →
Algal Oil DHA (Vegan) →
More evidence-based supplements
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.